 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...5455565758596061626364...100101» |
- ||| Verzenio (abemaciclib) / Eli Lilly
Clinical, P3 data, Journal: MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. (Pubmed Central) - Nov 6, 2020
P3
The most frequent grade ⩾3 adverse events in the abemaciclib arms were neutropenia, leukopenia, and anemia (both cohorts), and lymphocytopenia (cohort B). The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population.Trial Registration: ClinicalTrials.gov identifier: NCT02763566.
- ||| Ibrance (palbociclib) / Pfizer, Aliqopa (copanlisib) / Bayer
Enrollment closed, Enrollment change: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (clinicaltrials.gov) - Nov 6, 2020
P2, N=10, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population.Trial Registration: ClinicalTrials.gov identifier: NCT02763566. Suspended --> Active, not recruiting | N=102 --> 10
- | letrozole / Generic mfg., estradiol valerate / Generic mfg., clomifene citrate / Generic mfg.
New trial: the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women (clinicaltrials.gov) - Nov 5, 2020
P=N/A, N=160, Completed, Sponsor: Laylay Mohammed Khalleefah Alhibshi
- ||||| Herceptin (trastuzumab) / Roche
Clinical: Combination of #everolimus, #letrozole, & #trastuzumab has a favorable safety profile and shows anticancer activity in patients with hormone receptor and HER2-positive advanced cancers, Ballhausen et al report. @DavidHongMD @VivekSubbiah @FilipJankuMD https://t.co/DmclJxobD8 (Twitter) - Nov 5, 2020
- letrozole / Generic mfg., norethindrone / Generic mfg.
[VIRTUAL] Letrozole for successful medical management of Sciatica due to Extrapelvic Endometriosis () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_868;
Letrozole is a boon for extra pelvic endometriosis as it prevents peripheral conversion to estrogen. Therapeutic trial may be given to such patients who would otherwise require extensive surgery for lesion excision.
- letrozole / Generic mfg.
[VIRTUAL] Successful conception of a PCOS patient induced by pulsatile GnRH after failed ovulatory induction using letrozole: a case report () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_675;
*Corresponding Author: Prof. Xiangyan Ruan MD.
- letrozole / Generic mfg.
[VIRTUAL] Hyperandrogenic effects on female fertility and pregnancy outcome () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_492;
Widely used stimulation protocols for patients with hyperandrogenism and PCOS are Letrozole, Сlomiphene, as well as mini stimulation with recombinant gonadotropins...In patients with PCOS, in 70% of cases, non-receptive endometrium was detected, with premature maturation in most cases. The correct assessment of patients before the IVF treatment, as well as the preliminary preparation and normalization of hormonal levels and metabolism, positively affect the amount of mature oocytes, therefore the amount of euploid embryos and the maturity of the endometrium, significantly increase the chance of pregnancy in IVF cycles.
- [VIRTUAL] Aromatase inhibitors (AOI) in ART () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_488;
The aromatase inhibitors (AOI), which have letrozole as its main representative, have been increasingly used over the past years...Fertil Steril. 2005 84 Suppl 1.1O–231
- letrozole / Generic mfg.
[VIRTUAL] Letrozole versus clomiphene citrate: which is better for ovulation induction? () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_323;
For many years, drug of choice has been CC. However, this concept has been changing, making room for the use of LTZ, especially in PCOS patients, which is already considered by many authors a drug of choice in this pathology.
- Herceptin (trastuzumab) / Roche, Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
[VIRTUAL] Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2109;
P1
Background A previous phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival (OS) in patients treated with pelareorep (pela) in combination with paclitaxel (PTX) versus PTX alone.1 Given that pela is an intravenously delivered immuno-oncolytic reovirus, we hypothesized that the OS benefit from pela + PTX may be attributed to an adaptive T cell response triggered by pela...Five cohorts will be examined: Cohort 1: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole; Cohort 2: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole + atezolizumab; Cohort 3: TNBC (6 patients) receiving pelareorep + atezolizumab; Cohort 4: HER2+/HR+ (6 patients) receiving pelareorep + trastuzumab + atezolizumab; Cohort 5: HER2+/HR- (6 patients) receiving pelareorep + trastuzumab + atezolizumab...In general, most of the tissue-expanded T cell clones were also seen in the peripheral blood. Conclusions Overall, these preliminary data from cohort 1 of AWARE-1 demonstrate that pela mediates priming of a T cell-based immune response that occurs both systemically and within breast cancer tissue.
- Herceptin (trastuzumab) / Roche, Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
[VIRTUAL] Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_1969;
P1
Background A previous phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival (OS) in patients treated with pelareorep (pela) in combination with paclitaxel (PTX) versus PTX alone.1 Given that pela is an intravenously delivered immuno-oncolytic reovirus, we hypothesized that the OS benefit from pela + PTX may be attributed to an adaptive T cell response triggered by pela...Five cohorts will be examined: Cohort 1: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole; Cohort 2: HR+/HER2-neg (10 patients) receiving pelareorep + letrozole + atezolizumab; Cohort 3: TNBC (6 patients) receiving pelareorep + atezolizumab; Cohort 4: HER2+/HR+ (6 patients) receiving pelareorep + trastuzumab + atezolizumab; Cohort 5: HER2+/HR- (6 patients) receiving pelareorep + trastuzumab + atezolizumab...In general, most of the tissue-expanded T cell clones were also seen in the peripheral blood. Conclusions Overall, these preliminary data from cohort 1 of AWARE-1 demonstrate that pela mediates priming of a T cell-based immune response that occurs both systemically and within breast cancer tissue.
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Nov 3, 2020
P1, N=148, Recruiting, Sponsor: Pfizer
Conclusions Overall, these preliminary data from cohort 1 of AWARE-1 demonstrate that pela mediates priming of a T cell-based immune response that occurs both systemically and within breast cancer tissue. Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023
- |||| Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical: They carried out a trial with >4,000 patients looking at a biopsy at start of treatment and second biopsy two weeks later whilst the patient was on an aromatase inhibitor (anastrozole or letrozole)These biopsies were tested for Ki67 a marker of cell proliferation./2 (Twitter) - Nov 3, 2020
- ||| tagtociclib (PF-07104091) / Pfizer
Enrollment open, Combination therapy: PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) - Nov 2, 2020
P2, N=144, Recruiting, Sponsor: Pfizer
Trial completion date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
New P2 trial: Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (clinicaltrials.gov) - Nov 2, 2020
P2, N=60, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- |||| Herceptin (trastuzumab) / Roche
Clinical: Excited to have this come out in CCR: Tolerable safety profile and promising activity of everolimus, letrozole and trastuzumab in patients with HR+/HER2+ advanced cancers. https://t.co/3BqwbOHqEc Grateful to @FilipJankuMD for excellent mentorship! (Twitter) - Nov 2, 2020
- || letrozole / Generic mfg.
Retrospective data, Review: Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 1, 2020
Similar results were observed in the secondary analysis including only breast cancer patients. These findings are reassuring on the efficacy and safety of COS with gonadotropins and letrozole and are particularly important for fertility preservation in women with hormone-sensitive cancers.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Presentation 3 () - Oct 29, 2020 - Abstract #ESGO2020ESGO_120;
These findings are reassuring on the efficacy and safety of COS with gonadotropins and letrozole and are particularly important for fertility preservation in women with hormone-sensitive cancers. Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available)
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion (clinicaltrials.gov) - Oct 28, 2020
P4, N=110, Not yet recruiting, Sponsor: Shereen Rady Abou El-fetouh
Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available) Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Nov 2020 --> Mar 2021
- ||| PF-07248144 / Pfizer
New P1 trial, Metastases: C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 27, 2020
P1, N=110, Not yet recruiting, Sponsor: Pfizer
- | Ibrance (palbociclib) / Pfizer
Journal: Preparation and evaluation of Tc-labeled HYNIC-palbociclib analogs for cyclin-dependent kinase 4/6-positive tumor imaging. (Pubmed Central) - Oct 27, 2020
When mice were preinjected with palbociclib, tumor uptake of Tc-tricine-TPPTS-L significantly decreased and the tumor accumulation was clearly lost, confirming CDK4/6 specificity. All results in this work indicated that Tc-tricine-TPPTS-L is a promising tumor imaging agent that targets CDK4/6.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. (Pubmed Central) - Oct 27, 2020
Exposure of zebrafish embryos to complex 2 at concentrations around its in vitro cytotoxicity IC value (0.1-1 μM) did not lead to noticeable signs of toxicity over 96 h, making it a suitable candidate for further in vivo investigations. This study confirms the potential of Ru(II)Cp complexes for breasts cancer therapy, more specifically against TNBCs that are usually not responsive to currently used chemotherapeutic agents.
- | Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis
Enrollment open: Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients (clinicaltrials.gov) - Oct 26, 2020
P1/2, N=95, Recruiting, Sponsor: Yonsei University
This study confirms the potential of Ru(II)Cp complexes for breasts cancer therapy, more specifically against TNBCs that are usually not responsive to currently used chemotherapeutic agents. Not yet recruiting --> Recruiting
- |||||| amcenestrant (SAR439859) / Sanofi
Enrollment open, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 25, 2020
P3, N=810, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
New P2 trial, Metastases: ABIGAIL: ABemaciclib, ET (clinicaltrials.gov) - Oct 25, 2020
P2, N=160, Not yet recruiting, Sponsor: MedSIR
- | letrozole / Generic mfg.
Journal: Effect of exogenous hormones on R-spondin 1 (RSPO1) gene expression and embryo development in Pelodiscus sinensis. (Pubmed Central) - Oct 25, 2020
Feminisation was induced by oestradiol, but inhibited by letrozole. These results will contribute to studies of the potential molecular mechanisms underlying sex differentiation and sex control in the Chinese soft-shelled turtle.
- | letrozole / Generic mfg.
Preclinical, Journal: Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model. (Pubmed Central) - Oct 24, 2020
Letrozole was used to induce a PCOS model in rats, which were then randomly divided into four groups (n=9): Control, Model, high‑dose BGC (BGC‑H) and low‑dose BGC (BGC‑L) group...BGC also effectively reduced the level of IL‑6 and TNF‑α, and the expression of IKKβ, NF‑κB and SOCS3 in the hypothalamus of PCOS model rats. These results suggest that BGC may effectively improve hyperandrogenism, insulin resistance, endometrial receptivity and the low‑grade chronic inflammation in the hypothalamus.
- |||| Kisqali (ribociclib) / Novartis
Clinical: Nice work Scott! Your work in healthcare disparity And low-grade serous carcinoma will make a difference!! We will soon open GOG3026 evaluating ribociclib and letrozole for these patients. @GOG @RareOvarCancers @BrowardHealth @rcoledude (Twitter) - Oct 23, 2020
- | Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Phase classification, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Oct 23, 2020
P1/2, N=256, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
These results suggest that BGC may effectively improve hyperandrogenism, insulin resistance, endometrial receptivity and the low‑grade chronic inflammation in the hypothalamus. Phase classification: P1 --> P1/2
- ||| Kisqali (ribociclib) / Novartis
Trial completion date: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Oct 19, 2020
P3, N=668, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P1 --> P1/2 Trial completion date: Aug 2021 --> Aug 2022
- ||||| Orserdu (elacestrant) / Menarini
Enrollment closed, Monotherapy, Metastases: EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - Oct 19, 2020
P3, N=466, Active, not recruiting, Sponsor: Radius Pharmaceuticals, Inc.
Trial completion date: Aug 2021 --> Aug 2022 Recruiting --> Active, not recruiting
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Estas pastillas son tamoxifen, anastrozole,letrozole, exemestane. Pero estas pastillas pueden tener efectos secundarios, asi que solo se aplica a mujeres con alto riesgo de #CancerDemama. Es importante hablar con su medico #JuntosContraElCancer20 (Twitter) - Oct 19, 2020
- | letrozole / Generic mfg.
Trial initiation date: Myo-Inositol for Infertility in PCOS (clinicaltrials.gov) - Oct 19, 2020
P=N/A, N=168, Not yet recruiting, Sponsor: University of Oklahoma
Recruiting --> Active, not recruiting Initiation date: Jul 2020 --> Nov 2020
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Metastases: GOG-3039: Abemaciclib and Letrozole to Treat Endometrial Cancer (clinicaltrials.gov) - Oct 19, 2020
P2, N=50, Recruiting, Sponsor: Gynecologic Oncology Group
Initiation date: Jul 2020 --> Nov 2020 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
New P4 trial: Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion (clinicaltrials.gov) - Oct 19, 2020
P4, N=110, Not yet recruiting, Sponsor: Shereen Rady Abou El-fetouh
- | letrozole / Generic mfg.
New trial: Misoprostol With or Without Letrozole in Treatment of Missed Miscarriage (clinicaltrials.gov) - Oct 18, 2020
P, N=320, Active, not recruiting, Sponsor: Dr.Dalia Mohammed Al Sayed Zaki
- |||||| Ibrance (palbociclib) / Pfizer
Clinical, Video: VIDEO: ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for #EndometrialCancer w/ @MirzaCPH of @Rigshospitalet: https://t.co/pCyaPKYa6E @VJOncology @myESMO @OncoAlert #GyncSM #GynOnc #OncoAlert (Twitter) - Oct 17, 2020
- || Arimidex (anastrozole) / AstraZeneca, Remedica, Norditropin (somatropin) / Novo Nordisk
Clinical, Journal: Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. (Pubmed Central) - Oct 15, 2020
P=N/A
Data were obtained from the observational American Norditropin® Studies: Web-Enabled Research (ANSWER) Program, which collected efficacy and safety data of patients treated with Norditropin®...This trial was sponsored by Novo Nordisk and is registered with ClinicalTrials.gov (NCT01009905). Registered November 11, 2009; retrospectively registered.
- | Biomarker, Phase classification, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 14, 2020
P1, N=4000, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Registered November 11, 2009; retrospectively registered. Phase classification: P2 --> P1
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PALTAN: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (clinicaltrials.gov) - Oct 13, 2020
P2, N=26, Terminated, Sponsor: Washington University School of Medicine
Phase classification: P2 --> P1 N=48 --> 26 | Trial completion date: Dec 2021 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Aug 2020; Futility
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Oct 12, 2020
P1, N=148, Recruiting, Sponsor: Pfizer
N=48 --> 26 | Trial completion date: Dec 2021 --> Sep 2020 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Aug 2020; Futility Trial completion date: May 2022 --> Mar 2023 | Trial primary completion date: May 2022 --> Mar 2023
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] SECONDARY SPONTENEOUS PNEUMOTHORAX AS A PRESENTATION OF BREAST CANCER RECURRENCE: CASE REPORT () - Oct 12, 2020 - Abstract #CHEST2020CHEST_1981;
The most common type of malignancies associated with secondary spontaneous pneumothorax are primary lung cancer and sarcomas. To our knowledge, there are no cases that report an SSP as the presentation of breast cancer recurrence.
- | Verzenio (abemaciclib) / Eli Lilly
New P3 trial: POETIC-A: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (clinicaltrials.gov) - Oct 12, 2020
P3, N=2500, Not yet recruiting, Sponsor: Institute of Cancer Research, United Kingdom
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 12, 2020
P2, N=93, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
To our knowledge, there are no cases that report an SSP as the presentation of breast cancer recurrence. Trial primary completion date: Sep 2020 --> Sep 2021
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Real world evidence of Palbociclib use in Metastatic hormone positive HER negative metastatic breast cancer in Indian population (e-poster) - Oct 11, 2020 - Abstract #EBCCI2020EBCC-I_891;
In the study, 115 (61%) patients received palbociclib with Aromatase inhibitors either Letrozole or Anastrazole in the first line whereas 73 (39%) patients received it in the second line with Fulvestrant. The present real world data of palbociclib use in Indian population suggest similar effectiveness to previously published real world evidences and is standard of care in first and second line treatment of HR+/HER2- MBC.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Real world evidence of Palbociclib use in Metastatic hormone positive HER negative metastatic breast cancer in Indian population (e-poster) - Oct 11, 2020 - Abstract #EBCCI2020EBCC-I_890;
In the study, 115 (61%) patients received palbociclib with Aromatase inhibitors either Letrozole or Anastrazole in the first line whereas 73 (39%) patients received it in the second line with Fulvestrant. The present real world data of palbociclib use in Indian population suggest similar effectiveness to previously published real world evidences and is standard of care in first and second line treatment of HR+/HER2- MBC.
- || letrozole / Generic mfg.
Clinical, Journal: Short-term weight change and live birth among women with unexplained infertility and polycystic ovary syndrome undergoing ovulation induction. (Pubmed Central) - Oct 11, 2020
Women with PCOS gained an average of 2.2 kg regardless of the medication received, whereas women with UI experienced no short-term weight change during ovulation induction. Weight gain in women with PCOS was not associated with live birth rate.
- | A 443654 / AbbVie
Preclinical, Journal: GPR30-mediated estrogenic regulation of actin polymerization and spatial memory involves SRC-1 and PI3K-mTORC2 in the hippocampus of female mice. (Pubmed Central) - Oct 11, 2020
Weight gain in women with PCOS was not associated with live birth rate. Taking together, these results demonstrated that decreased GPR30 induces actin depolymerization through SRC-1 and PI3K/mTORC2 pathways and ultimately impairs learning and memory, indicating its potential role as a therapeutic target against hippocampus-based, E2-related memory impairments.
- | letrozole / Generic mfg.
Journal: Effect of electroacupuncture on levels of serum sex hormones and expression of ovarian auto-phagy related factors in rats with polycystic ovary syndrome (Pubmed Central) - Oct 10, 2020
Taking together, these results demonstrated that decreased GPR30 induces actin depolymerization through SRC-1 and PI3K/mTORC2 pathways and ultimately impairs learning and memory, indicating its potential role as a therapeutic target against hippocampus-based, E2-related memory impairments. EA intervention can reduce serum T, LH and AMH contents, and the ratio of ovarian LC3 Ⅱ/Ⅰ and up-regulate ovarian PI3K and AKT in PCOS rats, which may contribute to its effect in improving anovulatory infertility by suppressing autophagy.
- | letrozole / Generic mfg.
Journal: Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle. (Pubmed Central) - Oct 9, 2020
She underwent letrozole based frozen-thawed embryo transfer cycle after 4 months. One good quality blastocyst was transferred, and she conceived in the same cycle.